Importantly, the tumor inhibitory rate of HSA–NAMI-A–Cu(BpT)Br–DOX (ca. 44.8%) is about two-fold that of the three-agent combination (ca. 24.6%) and HSA-DOX (ca. 21.5%). Here, ALB is linked to neoplasm.